The Potential of Psychedelics: How Kyrsten Sinema is Championing Traumatic Brain Injury Treatment
Traumatic brain injuries (TBIs) affect millions worldwide, often leading to long-term cognitive, emotional, and behavioral challenges. Traditional treatments offer some relief, but many individuals continue to struggle with persistent symptoms. Now, former Arizona Senator Kyrsten Sinema is advocating for a novel approach: utilizing psychedelics to treat TBI. But is this a viable solution, or just a pipe dream?
The Scope of the Problem: Traumatic Brain Injuries
Approximately 69 million people worldwide suffer TBIs each year, with North America experiencing some of the highest rates. TBIs can result from a direct physical impact, leading to neuronal necrosis and tissue damage. While modern medicine has improved survival rates, the need for effective treatments remains critical due to the extended physical, cognitive, and psychological difficulties faced by survivors.
Common long-term challenges following a TBI include:
- Cognitive impairments: Memory loss, difficulty concentrating, and impaired decision-making.
- Emotional distress: Depression, anxiety, irritability, and mood swings.
- Behavioral changes: Impulsivity, aggression, and social withdrawal.
These symptoms can significantly impact daily life and hinder recovery, underscoring the urgent need for innovative therapeutic interventions.
Kyrsten Sinema’s Advocacy: A “Passion Project”
Kyrsten Sinema, a former U.S. Senator from Arizona, has emerged as a prominent advocate for psychedelic research, particularly in the context of TBI treatment. Since leaving the Senate in January 2025, Sinema has described this cause as a personal “passion project,” driven by the potential of psychedelics to address the limitations of conventional therapies.
Sinema’s interest in psychedelics was sparked by witnessing the transformative effects of ibogaine on a member of her security team who used it to treat a TBI. She noted that the individual “looked totally different — like 10 years younger” after the treatment. This experience led her to explore the potential of psychedelics, particularly ibogaine, in treating TBIs and other neurological disorders.
In a recent interview with CNN’s Jake Tapper, Sinema revealed that she had traveled to Mexico in May 2025 to try ibogaine herself, motivated by her late grandmother’s battle with dementia, which runs in her family. She expressed her fear of losing her brainpower and cited research suggesting that a single ibogaine treatment could reverse brain aging by 1.5 years.
House Bill 2871: A Step Towards Research
Sinema’s advocacy has translated into tangible legislative efforts. She lobbied Arizona lawmakers to allocate millions of dollars towards clinical research studies on ibogaine. This led to House Bill 2871, which proposed allocating \$5 million in state funding for clinical trials of ibogaine to treat PTSD, TBI, and Parkinson’s disease in Arizona. The bill passed the Arizona House of Representatives with bipartisan support and received unanimous approval from the Senate Appropriations Committee.
The bill requires \$5 million in matching funds from non-state sources, effectively creating a public-private partnership to support this research. While the bill has garnered support, it has also faced criticism from those who argue that the funding should be directed towards existing VA programs.
The Science Behind Psychedelics and TBI
The potential of psychedelics in treating TBI lies in their ability to influence several key aspects of brain function and recovery:
- Neuroplasticity: Psychedelics like psilocybin and LSD appear to increase communication between brain regions that don’t usually interact, potentially supporting neuroplasticity, a key factor in TBI recovery.
- Emotional Processing: TBI often leads to emotional dysregulation. Psychedelics may help individuals process trauma, reduce emotional distress, and gain a better understanding of their challenges.
- Anti-inflammatory Effects: Some studies suggest that psychedelics have anti-inflammatory properties, which could be beneficial in mitigating the neuroinflammation associated with TBI.
- Neurogenesis and Synaptogenesis: Psilocybin has demonstrated the ability to promote neurogenesis (the growth of new neurons) and synaptogenesis (the formation of new synapses), potentially helping to repair damaged brain areas and improve cognitive function.
A 2021 clinical trial at Johns Hopkins University explored the effects of psilocybin on veterans with mild to moderate TBI and associated PTSD. The study found that over 70% of participants reported significant reductions in anxiety, irritability, and depressive symptoms three months after treatment. Many participants also experienced improvements in cognitive functions, such as memory recall and mental clarity.
Ibogaine: A Closer Look
Ibogaine, a psychoactive alkaloid derived from the root bark of the Tabernanthe iboga shrub, has gained attention for its potential therapeutic properties, particularly in treating substance use disorders and, more recently, TBI-related symptoms. Unlike classic psychedelics, ibogaine is categorized as oneirogenic, producing immersive, dream-like states accompanied by extended periods of self-reflection.
A recent study published in Nature Mental Health provided initial evidence that ibogaine may alter brain activity and improve psychiatric symptoms in individuals with a history of TBI. The study found that magnesium-ibogaine therapy was associated with changes in cortical oscillations and neural complexity, which were linked to improvements in cognitive functioning, post-traumatic stress, and anxiety.
Legal and Ethical Considerations
Despite the promising research, significant legal and ethical hurdles remain. In the United States, ibogaine is classified as a Schedule 1 substance by the Drug Enforcement Administration (DEA), indicating a high potential for abuse and no accepted medical use. This classification restricts access to ibogaine and limits the scope of research that can be conducted.
However, attitudes towards psychedelics are evolving. Nine states in the U.S. have decriminalized psilocybin, and two have legalized assisted medical use. Additionally, legislation is expanding across the country to support psychedelic research and therapy, particularly for veterans.
The Path Forward
While the use of psychedelics for TBI treatment is still in its early stages, the potential benefits are significant. Kyrsten Sinema’s advocacy has brought much-needed attention to this area, and ongoing research is crucial to fully understand the efficacy and safety of these substances.
To advance this field, several steps are necessary:
- Further Clinical Trials: Larger-scale studies are needed to clarify dosage, frequency, and safety for TBI patients.
- FDA Approval: Securing FDA approval for psychedelic-assisted therapies is essential to make these treatments accessible to a wider population.
- Integration with Conventional Therapy: Psychedelic therapy is often most effective when combined with conventional treatments like cognitive-behavioral therapy (CBT) or occupational therapy.
- Safe and Supportive Environments: Psychedelic therapy for TBI should always be conducted in controlled, supervised environments with licensed therapists trained in trauma-informed care.
A Beacon of Hope
The journey to revolutionize mental health care for those who have suffered TBIs is ongoing. The inclusion of psychedelic research in legislative agendas marks a pivotal turn, promising innovative and effective treatments for those who have selflessly served our nation. As research continues, psychedelics may one day be part of a more holistic approach to TBI recovery, offering a beacon of hope for those seeking relief from the long-lasting effects of these injuries.